title: Review of 10 years of marketing experience with Chinese domestic inactivated hepatitis A vaccine Healive®.
abstract: In 2002, the first Chinese domestic preservative-free inactivated hepatitis A vaccine, Healive®, was introduced in China. It is highly immunogenic, and provides lasting protection in healthy individuals and generates protective levels of antibodies in other at-risk individuals. Over 10 years since its first licensure, postmarketing surveillance data have confirmed the outstanding safety profile of the vaccine. Comparative clinical trials indicated that Healive® induce equal or similar immunogenicity with other currently available inactivated hepatitis A vaccines and are interchangeable for the course of HAV immunization in Chinese children. The vaccine is effective in curbing outbreaks of hepatitis A due to rapid seroconversion and the long incubation period of the disease. Additional issues surrounding the use of the vaccine are also reviewed.
authors.affiliation: Clinical Research Department, Sinovac Biotech Co. Ltd., Beijing, P.R. China.
authors.forename: Jun-Yu
authors.initials: JY
authors.lastname: Wu
authors.forename: Yan
authors.initials: Y
authors.lastname: Liu
authors.forename: Jiang-Ting
authors.initials: JT
authors.lastname: Chen
authors.forename: Ming
authors.initials: M
authors.lastname: Xia
authors.forename: Xiao-Mei
authors.initials: XM
authors.lastname: Zhang
mesh_terms: D002681:China; D002986:Clinical Trials as Topic; D064420:Drug-Related Side Effects and Adverse Reactions / Q000453:epidemiology; D006506:Hepatitis A / Q000276:immunology / Q000517:prevention & control*; D022362:Hepatitis A Vaccines / Q000008:administration & dosage / Q000009:adverse effects* / Q000276:immunology*; D006801:Humans; D011358:Product Surveillance, Postmarketing; D015164:Vaccines, Inactivated / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology
chemical_list: D022362:Hepatitis A Vaccines; D015164:Vaccines, Inactivated